Market reaction
TuHURA Biosciences Inc (NASDAQ:HURA) saw its shares rise 7.4% on Friday after announcing that it had regained compliance with Nasdaq's minimum bid price standard. The company said it received written notice on Wednesday from Nasdaq Stock Market LLC confirming compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2).
Nasdaq confirmation and timing
According to the company statement, TuHURA's common stock maintained a closing bid price of $1.00 per share or greater for 11 consecutive business days, covering the period from February 10 through February 25, 2026. That stretch of closing prices satisfied the technical condition required by the listing rule and prompted Nasdaq's written confirmation.
Clinical and development programs
TuHURA is described as a Phase 3 immuno-oncology company focused on therapeutics designed to overcome resistance to cancer immunotherapy. The company is progressing enrollment in its Phase 3 accelerated approval trial for IFX-2.0 in front-line Merkel Cell Carcinoma. In parallel, TuHURA is preparing TBS 2025, a VISTA inhibiting antibody, for the initiation of a Phase 2 study targeting relapsed/refractory NPM1 mutated acute myeloid leukemia (AML).
In addition to its clinical-stage work, TuHURA said it is advancing toward preclinical proof-of-concept for a portfolio of first-in-class immune modulating antibody drug conjugates.
Management comment
Dr. James Bianco, President and CEO of TuHURA Biosciences, commented on the Nasdaq notice: "We are pleased to have regained full compliance with Nasdaq’s listing standards and continue to remain fully focused on advancing our pipeline of assets."
Context for investors
The Nasdaq confirmation restored a technical listing condition tied to the company's share price. TuHURA's public statement emphasizes ongoing clinical execution and preclinical progress as the firm directs attention to its development programs.
Note: This article provides a factual account of TuHURA Biosciences' Nasdaq compliance notice, recent share movement, and program status as reported by the company.